Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Scientech Medical Technology (Shanghai) Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.78.
During the past 12 months, the average EBIT per Share Growth Rate of Lepu Scientech Medical Technology (Shanghai) Co was 2.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 45.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 36.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
HKSE:02291'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 14.5 Med: 35.7 Max: 55.5
Current: 45.7
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Lepu Scientech Medical Technology (Shanghai) Co was 55.50% per year. The lowest was 14.50% per year. And the median was 35.70% per year.
HKSE:02291's 3-Year EBIT Growth Rate is ranked better than 86.8% of 682
companies
in the Medical Devices & Instruments industry
Industry Median: 9.75
vs HKSE:02291: 45.70
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lepu Scientech Medical Technology (Shanghai) Co EBIT per Share Related Terms
Lepu Scientech Medical Technology (Shanghai) Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co EBIT per Share Chart
Lepu Scientech Medical Technology (Shanghai) Co Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a EBIT per Share of HK$0.78 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. According to the industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #90 out of 682 companies in the Medical Devices & Instruments industry, placing it in the top 13.2%.
Is Lepu Scientech Medical Technology (Shanghai) Co's EBIT per Share too high?
Lepu Scientech Medical Technology (Shanghai) Co's current EBIT per Share is HK$0.78. Based on the distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #90 out of 682 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #90 out of 682 companies for EBIT per Share. This places Lepu Scientech Medical Technology (Shanghai) Co in the top 13% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.75, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Scientech Medical Technology (Shanghai) Co's current EBIT per Share is HK$0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$45.87, compared to a current price of HK$10.49 — trading 77.1% below its estimated fair value. The current EBIT per Share is HK$0.78. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current EBIT per Share is HK$0.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$10.49 is trading 77.1% below its estimated GF Value™ of HK$45.87.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
EBIT per Share: HK$0.78
GF Value™: HK$45.87 vs. price of HK$10.49 (77.1% below fair value)
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
82GF Score
Get the complete analysis for HKSE:02291
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
